Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone

Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients

(2013) JC Silva et al.   Clinics

Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals

(2012) Emileigh Mercer et al.   ARTHRITIS RESEARCH & THERAPY

The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study

(2012) L. Azoulay et al.   BMJ-British Medical Journal

Revised Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy

(2011) Michael F. Marmor et al.   OPHTHALMOLOGY

Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases

(2010) Laura R. Rekedal et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes

(2010) D. Williams-Herman et al.   DIABETES OBESITY & METABOLISM

Hydroxychloroquine and Glycemia in Women with Rheumatoid Arthritis and Systemic Lupus Erythematosus

(2010) S. K. PENN et al.   JOURNAL OF RHEUMATOLOGY

Role of Receptor-Interacting Protein 140 in human fat cells

(2010) Niklas Mejhert et al.   BMC Endocrine Disorders

Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes

(2009) P. Aschner et al.   DIABETES OBESITY & METABOLISM

Alpha glucosidase inhibitor voglibose can prevent pioglitazone-induced body weight gain in Type 2 diabetic patients

(2008) Mayumi Negishi et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY